NXS · ASX

Next Science Ltd (ASX:NXS)

AU$0.099

 0.003 (3.125%)
ASX:Live
09/05/2025 01:01:05 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NXS Overview

NXS Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NXS

Website

Next Science Ltd

Telephone

61.2.9188.7772

Address

Level 14 264-278 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. It operates through the North America, Australia and New Zealand geographical segments. The company was founded by Matthew Myntti on October 20, 2017 and is headquartered in Sydney, Australia.

NXS Price Chart

Key Stats

Market Cap

AU$28.05M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.08 - 0.39

Trade Value (12mth)

US$4,545.00

1 week

5.49%

1 month

-8.57%

YTD

-16.52%

1 year

-75.38%

All time high

4.73

Key Fundamentals

EPS 3 yr Growth

-23.60%

EBITDA Margin

-39.70%

Operating Cashflow

-$8m

Free Cash Flow Return

-83.20%

ROIC

-110.60%

Interest Coverage

-41.90

Quick Ratio

1.70

Other Data

Shares on Issue (Fully Dilluted)

292m

HALO Sector

Healthcare

Next Company Report Date

04-Mar-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

NXS Announcements

Latest Announcements

Date Announcements

05 May 25

Derivative complaint dismissed

×

Derivative complaint dismissed

02 May 25

Notification of cessation of securities - NXS

×

Notification of cessation of securities - NXS

24 April 25

Quarterly Activity Report & Appendix 4C - 31 March

×

Quarterly Activity Report & Appendix 4C - 31 March

17 April 25

2024 Annual Report

×

2024 Annual Report

17 April 25

Appendix 4G & 2025 Corporate Governance Statement

×

Appendix 4G & 2025 Corporate Governance Statement

11 April 25

Notice of 1Q FY25 Result and Investor Webinar

×

Notice of 1Q FY25 Result and Investor Webinar

04 April 25

2025 AGM - Notice of Meeting

×

2025 AGM - Notice of Meeting

14 March 25

Notice of Change of Share Registry

×

Notice of Change of Share Registry

11 March 25

2025 Annual General Meeting - Notification of dates

×

2025 Annual General Meeting - Notification of dates

03 March 25

Change in substantial holding from TEK

×

Change in substantial holding from TEK

03 March 25

Change in substantial holding from Tiga Trading Pty Ltd

×

Change in substantial holding from Tiga Trading Pty Ltd

28 February 25

FY24 Appendix 4E and Financial Report

×

FY24 Appendix 4E and Financial Report

28 February 25

Next Science reports FY24 Result

×

Next Science reports FY24 Result

28 February 25

FY24 Annual Result Investor Presentation

×

FY24 Annual Result Investor Presentation

25 February 25

Next Science receives FDA Warning Letter

×

Next Science receives FDA Warning Letter

07 February 25

Notice of FY24 Result and Investor Webinar

×

Notice of FY24 Result and Investor Webinar

29 January 25

Notification of cessation of securities - NXS

×

Notification of cessation of securities - NXS

23 January 25

Appendix 4C & Quarterly Activity Report - 31 December

×

Appendix 4C & Quarterly Activity Report - 31 December

20 January 25

Notice of 4Q FY24 Result and Investor Webinar

×

Notice of 4Q FY24 Result and Investor Webinar

08 January 25

Pause in Trading

×

Pause in Trading

08 January 25

Litigation involving former employee

×

Litigation involving former employee

28 October 24

Publication of XPERIENCE study showing 0% infection rate

×

Publication of XPERIENCE study showing 0% infection rate

24 October 24

NXS Presentation - Wilsons Drug & Device Conference

×

NXS Presentation - Wilsons Drug & Device Conference

22 October 24

Appendix 4C & Quarterly Activity Report - 30 September 2024

×

Appendix 4C & Quarterly Activity Report - 30 September 2024

16 October 24

Notice of 3Q FY24 Result and Investor Webinar

×

Notice of 3Q FY24 Result and Investor Webinar

NXS Fundamentals

Per Share Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.06 -0.07 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.06 -0.07 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.8 -15.4 47.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A 9.5 N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.05 -0.05 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.06 -0.07 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.5 7.7 45.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -11.9 -29.1 -36.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A 0.0 N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.04 0.04 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 0.04 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.0 36.6 -86.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 210 234 292 Lock Lock Lock
Basic m Lock Lock Lock Lock 210 234 292 Lock Lock Lock

Financial Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 12 22 23 Lock Lock Lock
     Growth % Lock Lock Lock Lock 30.9 89.4 2.9 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 21 31 27 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 8 15 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock 34.2 83.2 13.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock 70.5 68.2 75.3 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 30 32 25 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -12 -15 -9 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.8 -26.4 39.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -100.7 -67.2 -39.7 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -13 -16 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.1 -26.2 35.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -108.4 -72.3 -45.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -13 -16 -11 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -13 -16 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.7 -28.3 34.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -108.3 -73.4 -46.4 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -15 -8 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 10 20 2 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -12 -15 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -41.3 -29.3 47.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.0 -0.7 -0.4 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 5 9 2 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 12 18 9 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 1 1 2 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -4 -8 1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 4 5 6 Lock Lock Lock
Equity $m Lock Lock Lock Lock 8 12 4 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 9 14 6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -17.3 50.1 -57.7 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -101.8 -90.9 -114.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -154.4 -130.5 -288.7 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -127.0 -142.7 -105.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -129.6 -148.3 -110.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -120.5 -137.2 -83.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

USD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -412.5 -19.6 -41.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.3 0.6 -0.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -47.4 -66.7 22.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.2 3.6 1.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.8 3.5 1.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 61.9 66.4 27.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -452.2 -392.5 -247.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 8.9 8.5 6.5 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 3.0 9.1 7.7 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 2.0 2.3 7.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 17.3 6.2 4.3 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.9 1.2 2.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.9 1.2 2.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -108.3 -73.4 -46.4 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -101.8 -90.9 -114.9 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -101.8 -90.9 -114.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.5 1.4 2.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -154.4 -130.5 -288.7 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -154.4 -130.5 -288.7 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 122.4 40.2 47.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 40.9 42.7 56.2 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 163.3 82.9 103.7 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 196.4 87.5 75.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -33.0 -4.5 28.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

%

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NXS Shortsell

Frequently Asked Questions

The current share price of Next Science Ltd (NXS:ASX) is AU$0.099.
The 52-week high share price for Next Science Ltd (NXS:ASX) is AU$0.39.
The 52-week low share price for Next Science Ltd (NXS:ASX)? is AU$0.08.
Next Science Ltd (NXS:ASX) does not pay a dividend.
Next Science Ltd (NXS:ASX) does not pay a dividend.
Next Science Ltd (NXS:ASX) does not offer franking credits.
Next Science Ltd (NXS:ASX) is classified in the Healthcare.
The current P/E ratio for Next Science Ltd (NXS:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.